Coming off Wegovy without losing your progress: the 2026 evidence

What the evidence shows about regain

STEP-4 was the key trial. Patients on semaglutide who continued after 20 weeks of titration kept losing weight (additional 7.9% loss); those switched to placebo regained 6.9%. Real-world post-discontinuation data shows roughly half of lost weight returns within 12 months for most patients.

The mechanism is well understood: GLP-1s suppress appetite while taken; the underlying biology defending the higher weight (lower REE, elevated ghrelin, reduced leptin signaling) reasserts itself when the drug clears. Without structural intervention, weight follows.

Evidence-based strategies that minimize regain

1. Taper, don't quit cold-turkey. Drop one dose level (e.g., 2.4 → 1.7 mg) for 4-8 weeks, then 1.7 → 1.0, etc. Gives your body time to adapt and lets you assess regain rate at each level.

2. Maximize lean mass before stopping. The more muscle you have, the higher your REE, the easier maintenance is. 3 months of focused resistance training + 1.2-1.6g/kg protein before discontinuation pays off.

3. Structured nutrition coaching. Patients who work with a registered dietitian during the 6 months around discontinuation regain less than self-directed patients. This is the strongest non-medication lever.

4. Consider maintenance microdose if available. Some patients stay on 1.0 mg semaglutide or 5 mg tirzepatide indefinitely as 'metabolic maintenance.' Cheaper, lower side effect burden, prevents most regain. Discuss with prescriber.

5. Behavioral structure replacements. The mealtime structure GLP-1 gave you (smaller portions, fewer cravings) needs to be replaced by external structure: meal planning, defined eating windows, environmental management (what's in the house).

What doesn't work

'Detox' protocols, 'metabolism reset' supplements, intermittent fasting alone, willpower-based maintenance. None has evidence for preventing post-GLP-1 regain. Most actively undermine lean mass.